Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Borison

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Biological Psychiatry|June 1, 1980
Modulation of dopamine receptor sensitivity by estrogenJ H Gordon, R L Borison, B I Diamond
Lancet (London, England)|December 10, 1977
Potential of lithium as anaesthetic premedicantB I Diamond, H S Havdala, R L Borison
International Journal of Neurology|January 1, 1980
The role of substance P in the nigrostriatal systemR L Borison, H L Klawans, B I Diamond
Neuropharmacology|December 1, 1981
Site-specific blockade of dopamine receptors by neuroleptic agents in human brainR L Borison, J Z Fields, B I Diamond
Communications in Psychopharmacology|January 1, 1978
A new animal model for schizophrenia: cholinergic and serotonergic modulationR L Borison, H S Havdala, B I Diamond
Life Sciences|November 15, 1974
Biosynthesis of brain 2-phenylethylamine: influence of decarboxylase inhibitors and D-amphetamineR L Borison, A D Mosnaim, H C Sabelli
Journal of Clinical Psychopharmacology|June 1, 1995
Unexpected dystonia while changing from clozapine to risperidoneJ M Radford, T M Brown, R L Borison
Journal of Clinical Psychopharmacology|April 1, 1996
ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study GroupR L Borison, L A Arvanitis, B G Miller
Psychopharmacology Bulletin|January 1, 1994
Pharmacokinetics of risperidone in chronic schizophrenic patientsR L Borison, B Diamond, A Pathiraja, et al.
Advances in Neurology|January 1, 1984
Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's diseaseB I Diamond, G Pasinetti, A Hitri, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Biological Psychiatry|June 1, 1980
Modulation of dopamine receptor sensitivity by estrogenJ H Gordon, R L Borison, B I Diamond
Lancet (London, England)|December 10, 1977
Potential of lithium as anaesthetic premedicantB I Diamond, H S Havdala, R L Borison
International Journal of Neurology|January 1, 1980
The role of substance P in the nigrostriatal systemR L Borison, H L Klawans, B I Diamond
Neuropharmacology|December 1, 1981
Site-specific blockade of dopamine receptors by neuroleptic agents in human brainR L Borison, J Z Fields, B I Diamond
Communications in Psychopharmacology|January 1, 1978
A new animal model for schizophrenia: cholinergic and serotonergic modulationR L Borison, H S Havdala, B I Diamond
Life Sciences|November 15, 1974
Biosynthesis of brain 2-phenylethylamine: influence of decarboxylase inhibitors and D-amphetamineR L Borison, A D Mosnaim, H C Sabelli
Journal of Clinical Psychopharmacology|June 1, 1995
Unexpected dystonia while changing from clozapine to risperidoneJ M Radford, T M Brown, R L Borison
Journal of Clinical Psychopharmacology|April 1, 1996
ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study GroupR L Borison, L A Arvanitis, B G Miller
Psychopharmacology Bulletin|January 1, 1994
Pharmacokinetics of risperidone in chronic schizophrenic patientsR L Borison, B Diamond, A Pathiraja, et al.
Advances in Neurology|January 1, 1984
Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's diseaseB I Diamond, G Pasinetti, A Hitri, et al.
Pageof 7